Successful treatment of an intra-abdominal desmoid tumor with irinotecan, fluorouracil, and leucovorin plus bevacizumab in a patient with familial adenomatous polyposis

Costa, L. A.; Cezana, Loureno; Oliveira, Thiago Bueno; Dettino, Aldo Lourenço Abbade; Begnami, María Dirlei; Pinto, Clóvis Antônio Lopes; Fanelli, Marcello Ferretti; Mello, Celso Lopes

doi:10.1007/s00384-011-1201-0

Cited by 4 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore. new treatment protocols for IAF are gradually being recommended, such as imatinib [41], sunitinib [42], bevacizumab [43], or sorafenib [44]. However, the two cases reported had been treated with imatinib at a dose of 400 mg for liver metastatic GIST.…”

Section: Discussionmentioning

confidence: 99%

Subsequent intra-abdominal fibromatosis mimicking recurrent gastrointestinal stromal tumor

Jiang

Hou

et al. 2013

Diagn Pathol

View full text Add to dashboard Cite

Intra-abdominal fibromatosis (IAF) commonly develops in patients who had abdominal surgery. In rare instances, it occurs subsequent to gastrointestinal stromal tumor (GIST). This special situation has clinical significance in imatinib era. About 1000 patients with GIST in our institution from 1993 to 2010 were re-evaluated based on their clinical and pathological data, the treatment strategies and the follow-up information. We identified 2 patients who developed IAF after GIST resection. Patient 1 was a 54 year-old male and had 5 cm × 4.5 cm × 3.5 cm jejunal GIST excised on February 22, 1994. Three years later, an abdominal mass with 7 cm × 6 cm × 3 cm was identified. He was diagnosed as recurrent GIST from clinical point of view. After excision, the second tumor was confirmed to be IAF. Patient 2 was a 45-year-old male and had 6 cm × 4 cm × 3 cm duodenal GIST excised on August 19, 2008. One year later, a 4 cm mass was found at the original surgical site. The patient refused to take imatinib until the tumor increased to 8 cm six months later. The tumor continued to increase after 6 months’ imatinib therapy, decision of surgical resection was made by multidisciplinary team. The second tumor was confirmed to be IAF with size of 17 cm × 13 cm × 11 cm. Although IAF subsequent to GIST is very rare, it is of clinical significance in imatinib era as an influencing factor for making clinical decision.Virtual slidesThe virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1076715989961803

show abstract

Section: Discussionmentioning

confidence: 99%

Subsequent intra-abdominal fibromatosis mimicking recurrent gastrointestinal stromal tumor

Jiang

Hou

et al. 2013

Diagn Pathol

View full text Add to dashboard Cite

show abstract

“…Associations between DTFs and VEGF are but scarcely mentioned in the literature, however there are single reports of treatment success using anti-VEGF therapy [31,32].…”

Section: N) -Nuclear Positivity; (C) -Cytoplasmic Positivity; (M) -Membranous Positivity; --Negative Staining; +/--Weak; Focal Staining; mentioning

confidence: 99%

Immunohistochemical evaluation of potential molecular targets of desmoid-type fibromatosis

Janegová¹,

Hlavatá²,

Mihok³

et al. 2021

pjp

View full text Add to dashboard Cite

Desmoid-type fibromatosis is locally aggressive tumor rare in general population, although commonly present in patients with familial adenomatous polyposis, significantly contributing to the morbidity and mortality of patients. To optimize and individualize the management of patients it is necessary to better understand the biology of these tumors. Immunohistochemical analysis of β-catenin, VEGF, hormone receptors ERβ, ERα and PR, COX-2, APC protein, EGFR, c-kit (CD117), bcl-2 and HER2 expression, potential therapeutic targets, was carried out on 15 archival biopsy samples together with APC gene mutational screening. β-catenin expression was found in all samples, with over 73% showing high range positivity, however with no prognostic significance. Non-specific cytoplasmic localization of β-catenin was observed FAP-associated cases lacking CTNNB1 mutations. Hormone receptor status demonstrated expression of ERβ in 93% of lesions, without detectable ERα or PR. Distinct COX-2 expression of variable intensity was present in all but one desmoid-type fibromatosis case. All lesions demonstrated intense VEGF positivity. Immunoreactivity for the APC protein was found only in 4 cases associated with FAP. No EGFR, HER2, bcl-2 or c-kit expression was detected in any sample. Expression of β-catenin, VEGF, ERβ, COX-2 in high number of cases suggests a potential as future therapeutic targets in desmoid-type fibromatosis.

show abstract

Diseases of the Peritoneum, Retroperitoneum, Mesentery, and Omentum

Larson

Evers

2015

Yamada' S Textbook of Gastroenterology

View full text Add to dashboard Cite

Successful treatment of an intra-abdominal desmoid tumor with irinotecan, fluorouracil, and leucovorin plus bevacizumab in a patient with familial adenomatous polyposis

Cited by 4 publications

References 18 publications

Subsequent intra-abdominal fibromatosis mimicking recurrent gastrointestinal stromal tumor

Subsequent intra-abdominal fibromatosis mimicking recurrent gastrointestinal stromal tumor

Immunohistochemical evaluation of potential molecular targets of desmoid-type fibromatosis

Diseases of the Peritoneum, Retroperitoneum, Mesentery, and Omentum

Contact Info

Product

Resources

About